Fugen Li

Dana-Farber Cancer Institute — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

28h-index4.2kcitations163works0.72yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(37), Lung Cancer Treatments and Mutations(16), RNA modifications and cancer(16), Cholangiocarcinoma and Gallbladder Cancer Studies(15), Radiomics and Machine Learning in Medical Imaging(13)

Publications163 total

Abstract PR022: Polycomb dysregulation shapes chromatin bivalency critical for prostate cancer lineage plasticity
Cancer Research·2026
Abstract B078: MYCL drives lineage plasticity and resistance to androgen receptor inhibition in castration-resistant prostate cancer
Cancer Research·2026
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with MET exon 14 skipping mutated non-small cell lung cancer
Translational Lung Cancer Research·2025Open Access
Safety and efficacy of HH2853, a novel EZH1/2 dual inhibitor, in patients with refractory solid tumours or non-Hodgkin lymphomas: a phase I study
EClinicalMedicine·2025· 1 citedOpen Access
A multicenter, open-label, single-arm, phase Ib clinical trial of HH2853 treatment in patients with relapsed and/or refractory peripheral T-cell lymphoma
Journal of Hematology & Oncology·2025· 1 citedOpen Access
A novel technique for NO.253 lymph node dissection and left colic artery preservation to avoid potential postoperative internal hernia in laparoscopic radical resection for rectal cancer
BMC Surgery·2024· 2 citedOpen Access
A pooled analysis of clinical outcome in driver-gene negative non-small cell lung cancer patients with MET overexpression treated with gumarontinib
Therapeutic Advances in Medical Oncology·2024· 1 citedOpen Access
A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial of HH2853 in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma
Blood·2023· 3 citedOpen Access
Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial
EClinicalMedicine·2023· 48 citedOpen Access
Data from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Supplementary Table 3 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Supplementary Figures S1 - S5, Tables S1 - S2 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Supplementary Figures S1 - S5, Tables S1 - S2 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Data from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Supplementary Methods from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Supplementary Methods from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Supplementary Table 3 from Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer
2023Open Access
Fabrication of anode supported solid oxide electrolysis cell with the co-tape casting technique and study on co-electrolysis characteristics
Journal of Power Sources·2023· 26 cited
Residues and dietary risk assessment of fluazinam in root mustard after field experiments
Environmental Science and Pollution Research·2023· 3 cited
A Novel Technique With Ileal Mesentery to Reconstruct the Pelvic Peritoneum After Pelvic Dissection With End Colostomy for Rectal Cancer
Diseases of the Colon & Rectum·2022· 5 cited
page 1 of 9Next →

Frequent Co-authors

Dadong Zhang(13), Henry W. Long(9), Myles Brown(8), Lei Xiong(7), Xiaoya Xu(5), Dong Hua(4), Xinkai Cao(4), Zishuo Chen(4), Hao Qin(4), Mark M. Pomerantz(3), Matthew L. Freedman(3), Gary D. Stormo(3), Zhenghua Xie(3), Henrik Grönberg(3), Jiajia Xu(3), Hao Chen(3), Wenjun Luo(3), Zhengwen Xu(3), Yingdong Jia(3), Stuart S. Levine(2)